G418-Mediated

ABSRACT
Autosomal recessive proximal renal tubular acidosis is caused by mutations in the SLC4A4 gene encoding the electrogenic sodium bicarbonate cotransporter NBCE1-A (NBCe1). The mutations that have been characterized thus far result in premature truncation, mistargeting or decreased function of the cotransporter. Despite bicarbonate treatment to correct the metabolic acidosis, extrarenal manifestations persist including glaucoma, cataracts, corneal opacification and mental retardation. Currently, there are no known therapeutic approaches that can specifically target mutant NBCE1-A proteins. In the present study, we tested the hypothesis that the NBCe1-A-Q29X mutation can be rescued in vitro by treatment with aminoglycoside antibiotics, which are known for their ability to suppress premature stop codons. As a model system, we cloned the NBCe1-A-Q29X mutant into a vector lacking an aminoglycoside resistance gene and transfected the mutant cotransporter in HEK293-H cells. Cells transfected with the NBCe1-A-Q29X mutant failed to express the cotransporter because of the premature stop codon. Treatment of the cells with G418 significantly increased the expression of the full-length cotransporter as assessed by immunoblot analysis. Furthermore, immunohistochemistry studies demonstrated that G418 treatment induced cotransporter expression on the plasma membrane whereas in the absence of G418, NBCe1-A-Q29X was not expressed. In HEK293-H cells transfected with the NBCe1-A-Q29X mutant not treated with G418, NBCe1-A-mediated flux was not detectable. In contrast, in cells transfected with the NBCe1-A-Q29X mutant, G418 treatment induced a Na + -and HCO 3 --dependant transport that did not differ from wild-type NBCe1-A function. G418 treatment in mocktransfected cells was without effect. In conclusion, G418 induces ribosomal read-through of the NBCe1-A-Q29X mutation in HEK293-H cells. These findings represent the first evidence that in the presence of the NBCe1-A-Q29X mutation that causes proximal renal tubular acidosis, fulllength functional NBCe1-A protein can be produced. Our results provide the first demonstration of a mutation in NBCe1-A that has been treated in a targeted and specific manner.
Autosomal recessive proximal renal tubular acidosis is characterized by severe proximal tubule bicarbonate wasting, hyperchloremic metabolic acidosis and hypokalemia (11, 20, 21, (25) (26) (27) 39, 50, 54) . In addition to a renal phenotype, these patients have extra-renal manifestations involving the eye that includes glaucoma, cataracts, and band keratopathy. Mental retardation, short stature, teeth abnormalities, an elevated serum amylase, thyroid abnormalities, and basal ganglia calcification have also been reported (11, 20, 21, (25) (26) (27) 39, 50, 54 (46) . Currently 10 unique mutations throughout the cotransporter have been reported. The location of these mutations is depicted in Figure 1 based on one of the putative current topologic models of NBCe1.
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Of the known mutations in NBCe1, three mutations that cause premature truncation of the cotransporter have been described (21, 26, 27) . In the NBCe1-A-Q29X nonsense mutation causing proximal RTA, a wt-CAG codon encoding glutamine has been replaced by a UAG stop codon resulting in premature truncation of the cotransporter (26) . NBCe1 has three functional variants, NBCe1-A, NBCe1-B, and NBCe1-C, however only NBCe1-A possesses a unique N-terminus containing Gln-29 and is therefore the only variant prematurely truncated in these patients as a result of the Q29X mutation. As a separate approach, treatment of diseases caused by premature stop codons (PSC)
pharmacologically by inducing ribosomal read-through has received increasing attention recently.
In this regard, aminoglycosides or their derivatives offer a potential therapeutic approach to treat PSC mutations by inducing ribosomal read-through (9, 29, 44, 59 ). In addition, PTC124, a compound unrelated to aminoglycosides in some systems is capable of inducing ribosomal readthrough and is currently being tested in various trials (62) .
No therapeutic approaches are available for treating patients with hereditary proximal renal tubular acidosis other than bicarbonate therapy. Although bicarbonate therapy ameliorates the systemic acidemia in these patients, more specific approaches that target identified mutations throughout the cotransporter would potentially have an important role in ameliorating the extrarenal manifestations that involve the eye and the brain. In the present study, we having taken a first step in this regard and have addressed the question as to whether the NBCe1-A-Q29X mutation can be rescued in vitro by treatment with an aminoglycoside antibiotic. We utilized G418 as a test compound. Our results are encouraging in that they represent the first demonstration that G418 induces ribosomal read-through of the NBCe1-A-Q29X mutation producing full-length functional NBCe1-A protein. In experiments where an aminoglycoside was used to induce ribosomal read-through, the cells were exposed to G418 (Invitrogen, 75 Ig/ml) for 24 h prior to study. For these studies, G418 was dissolved directly at its final concentration in DMEM supplemented with 10% fetal bovine serum and 200 mg/l L-glutamine. Control experiments were preformed on cells exposed to the identical media without G418. Immunoresearch, West Grove, PA) was used at a dilution 1:10,000. The bands were visualized using an ECL kit and Hyperfilm ECL (GE HealthCare).
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MATERIALS AND METHODS
Transient Expression in HEK293-H cells
SDS-PAGE, Western blotting and Immunoprecipitation
In experiments assessing the rate of induction of NBCe1-A in response to G418, cells transiently expressing the mutant plasmid were exposed 8 h after transfection to G418 (Invitrogen, 75 µg/ml) in DMEM/10% fetal bovine serum. The cells were incubated for various times up to 72 h at 37°C. at 95°C. The samples were analyzed by SDS-PAGE and Western blotting. In the G418 removal time course protocol, the media containing G418 (75 µg/ml) was removed 24 hours after initial incubation and the cells were assayed at various subsequent time points for NBCe1-A expression.
Quantitative PCR
Quantitative PCR was used to determine the effect of Geneticin (G418) on the levels of mRNA for wild type NBCe1-A and the Q29X mutant. Total RNA was isolated from transfected HEK293-H cells using RNeasy spin columns (RNeasy Mini Kit; Qiagen) according to the manufacturer's instructions. The samples were treated both on-column and off-column with RNase-free DNase (Qiagen) to achieve sufficiently pure total RNA samples. First-strand cDNA was synthesized using Omniscript (Qiagen) in a 20 µl assay containing 2 µl of 10× RT buffer, 0.5 mM each dNTP, The results were analyzed using Opticon Monitor Analysis Software, Version 1.08 (MJ Research).
To use the relative quantitative analysis, a validation experiment was performed as recommended by the manufacturer. Standard curves were generated by plotting the values of the threshold-crossing points against log-transformed copy numbers of standard templates. They were linear both NBCe1-A and GAPDH in a range of 25.6-10 7 copies/µl. The levels of wild type and the Q29X mutant of NBCe1-A mRNAs in various total RNA preparations were normalized by the level of GAPDH mRNA in a given sample. Each experiment was performed in triplicate wells.
G418 assay
Intracellular G418 content was measured in HEK-H cells according to Bethune et al (6) . Initially, a standard curve was generated using a stock solution of G418 sulfate (10 mg/ml) prepared in 0.02 M borate buffer, pH 8. To assay the dose dependence of intracellular G418 in HEK-H cells, the cells were exposed to various concentrations of G418 (0, 18.75, 37.5, 75, 150, 225, 300 µg/ml) in DMEM/10% fetal bovine serum. The cell monolayers were incubated at each G418 concentration at 37°C (5% CO 2 ) for 24 h. were expressed as a ratio of G418 per amount of protein in the sample. Cell protein was determined using Bradford reagent (Sigma) with absorbance measured at 595 nm. In the G418 removal time course protocol, the cells were exposed to G418 (75 µg/ml) for 24 hours after which the compound was removed from the media and intracellular G418 was assayed at various subsequent time points.
Immunohistochemistry
Approximately 24 h following transfection, HEK293-H cells growing on circular coverslips were rinsed twice with 1x PBS and processed for examination by immunofluorescence microscopy.
The cells were incubated for 2 min in 1 ml of methanol ( 4°C) and then rinsed twice with 1x PBS.
A previously well-characterized NBCe1-A specific antibody (8) was applied at 1:100 dilution in PBS for 1 h at room temperature. After several washes in PBS, goat anti-rabbit IgG conjugated with Cy3 (1:500 dilution; Jackson ImmunoResearch) was applied for 1 h at room temperature.
The slides were rinsed in PBS, treated with 4% paraformaldehyde and mounted in Crystal/Mount (Biomeda, Foster City, CA). A liquid-cooled PXL charge-coupled device camera (model CH1;
Photometrics), coupled to a Nikon Microphot-FXA epifluorescence microscope, was used to capture and digitize the fluorescence images.
Functional Studies
Functional studies were performed 24 h after transfection. In these experiments, Intracellular pH (pH i ) was monitored using the fluorescent probe probe 2',7'-bis(2-carboxyethyl)-5(6)- 
Statistics
Dunnett's t-test was used to compare group means when more than one experimental group was compared with a control group. A value of p < 0.05 was considered statistically significant.
RESULTS
Effect of G418 on NBCe1-A-Q29X Expression: Immunoblot Analysis
The following experimental groups were studied. 1) Mock transfected cells; 2) Mock transfected cells plus G418; 3) wt-NBCe1-A transfected cells; 4) wt-NBCe1-A transfected cells plus G418; 5)
NBCe1-A-Q29X transfected cells; and 6) NBCe1-A-Q29X transfected cells plus G418. As shown in Figure 2 in mock transfected cells in the presence or absence of G418, no bands were seen.
From cells expressing wt-NBCe1-A with or without G418, a ~ 130 kDa band was detected corresponding to the expected size of the NBCe1-A monomer. In cells transfected with the Q29X mutant the ~ 130 kDa band corresponding to the full-length cotransporter was absent due to the extreme N-terminal missence mutation. However, in the presence of G418, a band of the expected size was detected suggested that G418 induced ribosomal read-through.
Effect of G418 on NBCe1-A-Q29X Expression: Immunohistochemistry
HEK293-H cells expressing wt-NBCe1-A or NBCe1-A-Q29X are shown in Figure 3 . NBCe1-A is expressed on the plasma membrane as expected. In contrast HEK293-H cells fail to express the NBCe1-A-Q29X mutant corroborating the immunoblot results. However in the presence of G418, the cotransporter was expressed indicating that ribosomal read-through had been induced.
Moreover, the staining pattern was similar to the wild-type transporter.
Rate of Induction of NBCe1-A Expression Induced by G418 in Cells Expressing NBCe1-A-Q29X
The rate of induction of NBCe1-A expression following G418 treatment is shown in Figure 4 . By 20 h following continuous exposure to G418 (75 µg/ml), the level of protein expression was weakly detectable by immunoblot analysis. NBCe1-A was strongly expressed by 24 h and remained detectable at 72 h.
Lack of Effect of G418 on NBCe1-A-Q29X Message Level
Although G418 is known to cause ribosomal read-through, additional experiments were done to determine whether G418 affects NBCe1-A message levels. As shown in Figure 5 , there were no significant changes in mRNA expression of either wild type or mutant NBCe1-A in cells treated with G418. These results indicate that the expression of the full length NBCe1-A protein in cells transfected with the NBCe1-A-Q29X mutant is not mediated by changes in mRNA levels but takes place at the level of protein translation.
Analysis of HEH293-H Cell G418 content
Since the effect of G418 is mediated intracellularly, we developed an assay system to determine the content of HEK293-H cells as a function of the extracellular G418
concentration. As shown in Figure 6 the cellular G418 content varied directly with the media G418 concentration. The mean G418 content in cells exposed to 75 µg/ml was 15.2 +/-2.2 ng/mg protein (n = 4, cells grown in 10 cm plates). In separate experiments, G418 was removed from the media after initial induction of NBCe1-A expression ( Figure 6 ). Following the removal of media G418, both cellular G418 content and NBCe1-A expression by immunoblot analysis was measured as a function of time. The results in Figure 6 show that the total cellular content of G418 decreases slowly following its removal from the extracellular medium suggesting that the intracellular pool of G418 is bound and/or compartmentized. The expression of NBCe1-A protein was detectable at 120 hours following the removal of G418.
Functional studies
The results of the functional studies are shown in Figure 7 . Representative experiments are shown in Figure 7 and the summary of the results in each experimental protocol is shown in Figure 8 . In mock transfected cells, G418 had no effect on the low background rate of pH i recovery. In cell expressing wt-NBCe1-A, the rate of Na + -dependent pH i recovery was significantly increased to ~1.0 pH/min (p < 0.001) versus mock transfected cells. G418 was without effect in cells transfected with the wild-type cotransorter. As shown in Figure 7 and 8, in cells expressing the NBCe1-A-Q29X mutant, the background rate of Na + -dependent pH i recovery was similar to mock transfected cells. However, in the presence of G418, cells expressing the NBCe1-A-Q29X mutant had a brisk Na + -dependent pH i recovery rate that was not significantly different from cells expressing the wild-type cotransporter (p = NS). These results demonstrate that G418 had induced the expression of functional NBCe1-A despite the presence of a nonsense mutation in its extreme N-terminus.
DISCUSSION
In the present study, we have shown for the first time that in cells expressing mutant NBCe1-A-Q29X, aminoglycoside induced-ribosomal read-through induces the production of full-length protein.
Although we can't be certain of the residue that was substituted for the UAG stop codon, the most frequently reported substitution for the UAG stop codon is CAG which encodes glutamine (40) . Glutamine is fortuitously the residue present at this location in wt-NBCe1-A and likely accounts for the finding that the cotransporter was fully functional following G418 treatment severe phenotype (68) . Therefore, it has been suggested that it is primarily in recessive disorders that aminoglycosides hold the greatest promise to ameliorate the abnormal phenotype (68) . In this regard, it would be of interest and potentially of therapeutic importance to determine the minimum number of NBCe1-A transporters required to ameliorate the bicarbonate absorptive defect.
In vitro, the aminoglycoside G-418 has the best termination suppression activity (41) . Its use as a therapeutic agent is not feasible systemically since it is lethal even at very low concentrations.
Specifically, the LC 50 of G-418 against human fibroblast cells is 0.04 mg ml (35, 36) . Two different conformations of the free cytoplasmic A-site were reported that corresponded with its "on" state, with the two adenine residues A1492 and A1493 fully extruding, and its "off" state, with A1491 fully extruded and A1493 partially extruded (36) . These findings suggest that the aminoglycoside apramycin specifically binds and stabilizes the non-decoding "off" state of the cytoplasmic A site thereby inhibiting translocation of the eukaryotic ribosome rather than disturbing decoding fidelity as in prokaryotes (19, 35, 37) . Importantly, there are still no structures of the human A-site in complex with any of the aminoglycosides that induce read-through.
Despite their ability to induce ribosomal read-through, the known nephrotoxic and ototoxic complications of aminoglycosides limits the use of this class of drugs therapeutically in patients with PSC mutations (43) . The origin of this toxicity is multifactorial including but not limited to interactions with phospholipids, inhibition of phospholipases, formation of free radicals, binding to both the eukaryotic ribosomal A-site and mitochondrial 12S rRNA A-site. To limit the toxicity various approaches are being attempted including: 1) the use of antioxidants to reduce free radical levels (31,51) 2) poly-L-aspartate (4,13) and daptomycin (55, 56) to reduce the ability of aminoglycosides to interact with phospholipids; and 3) the administration of agonists that compete for aminoglycoside binding to megalin (61); 4) structural modification that limit toxicity without altering the efficacy of PSC read-through (45) and the isolation of a non-nephrotoxic aminoglycoside (gentamicin) congener (49) . Whether any of these approaches will turn out in the long run to be accepted is currently unknown.
Patients with NBCe1-A mutations are known to have band keratopathy, cataracts, and glaucoma.
The eye phenotype can potentially be debilitating and lead to blindness (11, 20, 21, (25) (26) (27) . Of interest is the finding that the Q29X mutation which is selective for NBCe1-A (sparing NBCe1-B
and NBCe1-C) does not result in cataracts, or band keratopathy as do mutations that effect all variants (26) . The latter may be due to differences in the expression of NBCe1 variants in various regions of the eye (8, 57) . In general, the eye appears a priori to be an easier target for drug therapy than the kidney. Of the three eye abnormalities present in most patients with NBCe1
mutations affecting NBCe1A and NBCe1-B, band keratopathy being a corneal abnormality would be most susceptible to topical therapy and is currently treated with EDTA chelation of calcium deposition. The treatment of cataracts and glaucoma would require agents, which are more permeable. In the context of the Q29X mutation that spares the cornea, the highly hydrophilic structure of gentamicin limits its permeability through biological membranes, resulting in low ocular bioavailability and posing a pharmacokinetic limitation to the drug's reaching therapeutic concentrations at the site of action in the eye. Although intraocular injections can theoretically deliver higher amounts of drug to potentially treat the glaucoma in a patient with the Q29X mutation and other intraocular diseases caused by missense mutations (15) (16) (17) 52, 58, 65) , compared with eye drop instillation, their administration is painful, requires a physician, and is associated with severe complications such as perforation of the globe and scarring of the conjunctiva.
In summary, our results demonstrate for the first time that a nonsense mutation in NBCe1-A known to cause proximal renal tubular acidosis can be corrected in vitro using the aminoglycoside G418. These results add to the compelling evidence that certain aminoglycoside structures can induce mammalian ribosomes to read-through premature stop codon mutations and generate fulllength functional proteins. The development of purmomycin analogues with improved readthrough capability (45) , and chemically unrelated compounds such PTC124 (62) suggest that goal of developing clinically useful agents may be an achievable goal in the not too distant future. 
